While a study in healthy volunteers demonstrated bioequivalence of the 2 insulin products, to date, few direct comparisons of the biosimilar and the innovator have been available. A new study compared the efficacy and safety of treatment with each of the products in a retrospective analysis of hospitalized patients with type 2 diabetes and found that the reference insulin provided better fasting glycemic control than the biosimilar.
Currently, 2 insulin glargine products are available in China: Sanofi’s innovator drug, Lantus, and a biosimilar produced by Gan and Lee that is sold under the name Basalin. While a study in healthy volunteers demonstrated bioequivalence of the 2 insulin products, to date, few direct comparisons of the biosimilar and the innovator have been available. A new study compared the efficacy and safety of treatment with each of the products in a retrospective analysis of hospitalized patients with type 2 diabetes and found that the reference insulin provided better fasting glycemic control than the biosimilar.
The study used electronic medical records for patients who were hospitalized in noncritical settings at a single center in China between 2006 and 2017. The patients were admitted primarily as a result of uncontrolled hyperglycemia. Patients were treated with subcutaneous injection of basal insulin, together with or without mealtime insulin or oral antihyperglycemic drugs.
Whether patients received the biosimilar or the reference insulin glargine depended on insurance coverage, affordability, and patient access after discharge.
In total, 47 patients received the biosimilar and 429 received the reference. Propensity score matching was conducted to minimize selection biases that could confound comparisons between basal insulin treatments. Before matching, there were marked differences between groups in terms of duration of diabetes and the proportion of male patients. After matching, 34 patients who received the biosimilar and 101 patients who used the reference were considered.
In the matched group, patients who received the reference had a significantly greater mean reduction in fasting blood glucose (−2.20 mmol/L) than those who received the biosimilar (−1.24 mmol/L; P  = .04). The mean fasting blood glucose value was also numerically lower for patients treated with the reference (7.26 mmol/L) than with the biosimilar (8.20 mmol/L; P  = .12).
Patients receiving the reference tended to have lower mean postbreakfast and prelunch blood glucose levels compared with those receiving the biosimilar, but this trend did not reach statistical significance.
The incidence of hypoglycemia was low and comparable between groups.
The authors note that the study was limited by the short duration of treatment and the single-center setting. Further investigations should include a randomized controlled trial to investigate whether changes to treatment practice favoring the reference insulin glargine can be recommended.
Basalin, the biosimilar considered in this study, is not yet approved in the United States. However, according to a December 2018 agreement, Gan and Lee’s insulin products will be commercialized by biosimilar developer Sandoz in the European Union, United States, Switzerland, Japan, South Korea, Canada, Australia, and New Zealand.
Reference
Hu X, Zhang L, Dong C, Dong Y, Jiang J, Gao W. A propensity score matched comparison of brand and biosimilar basal insulin in non-critical hospitalized patients with type 2 diabetes mellitus [published online March 21, 2019]. Adv Ther. doi: 10.1007/s12325-019-00922-9.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
"Not So Different": How the BPCIA Transition Will Affect Biosimilar Uptake
April 10th 2020This week on the podcast, we’re speaking with the executive director of the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC), Cate Lockhart, PharmD, PhD, about the acceptance process for biosimilars in the United States, what BBCIC is doing to help the market develop, and how the new approval pathway for biologics will affect the pace at which biosimilars come to market.
Biosimilars Fuel Price Cuts in European Insulin Glargine Markets
February 14th 2025Although Lantus continues to lead the insulin glargine market globally, the rise of biosimilars like Abasaglar and Semglee has sparked significant price reductions, with some European countries seeing discounts of up to 42.3%.
Aflibercept Biosimilar MYL-1701P Provides Equivalence in DME Therapy
November 27th 2024The study findings demonstrate that the aflibercept biosimilar MYL-1701P is as effective and safe as the reference aflibercept in treating diabetic macular edema (DME), offering a promising option for reducing treatment costs and improving global access to care for patients with DME.
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.